Diabetics using TZDs face higher bladder cancer risk
This article was originally published in Scrip
Executive Summary
Patients taking thiazolidinedione (TZD) drugs – which account for up to 20% of drugs prescribed to diabetics in the US – are two to three times more likely to develop bladder cancer than those taking a sulfonylurea drug, according to a new study published online in the Journal of the National Cancer Institute by researchers from the Perelmen School of Medicine at the University of Pennsylvania.